Loading...
XNASRNXT
Market cap31mUSD
Jan 08, Last price  
1.32USD
1D
-3.65%
1Q
32.65%
IPO
-81.82%
Name

RenovoRx Inc

Chart & Performance

D1W1MN
XNAS:RNXT chart
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
0k
Net income
-10m
L+4.72%
-3,776,000-4,385,000-7,096,000-9,771,000-10,232,000
CFO
-10m
L+16.42%
-3,350,000-3,528,000-5,916,000-8,811,000-10,258,000
Earnings
Jun 06, 2025

Profile

RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.
URL
https://renovorx.com/
IPO date
Aug 17, 2021
Employees
10
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑12
Income
Revenues
Cost of revenue
11,396
9,956
Unusual Expense (Income)
NOPBT
(11,396)
(9,956)
NOPBT Margin
Operating Taxes
(118)
Tax Rate
NOPAT
(11,396)
(9,838)
Net income
(10,232)
4.72%
(9,771)
37.70%
Dividends
Dividend yield
Proceeds from repurchase of equity
5,000
42
BB yield
-21.22%
-0.20%
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
3,291
568
Net debt
(1,173)
(6,440)
Cash flow
Cash from operating activities
(10,258)
(8,811)
CAPEX
Cash from investing activities
2,032
(2,032)
Cash from financing activities
5,008
42
FCF
(11,396)
(9,681)
Balance
Cash
1,173
6,440
Long term investments
Excess cash
1,173
6,440
Stockholders' equity
(41,404)
(24,992)
Invested Capital
41,695
31,155
ROIC
ROCE
EV
Common stock shares outstanding
10,291
9,052
Price
2.29
-2.55%
2.35
-51.45%
Market cap
23,566
10.78%
21,272
-50.81%
EV
22,393
20,995
EBITDA
(11,396)
(9,950)
EV/EBITDA
Interest
108
57
Interest/NOPBT